Table 3

Risk factors for 30-day mortality among patients with community-onsetKlebsiella pneumoniaebloodstream infection in univariate analysis
No. of survivors No. of non-survivors OR (95% CI) p
(n = 456) (n = 97)
Age (year) (mean ±SD) 61.1 (±13.5) 63.3 (±12.1) 0.146
Male sex 287 (62.9) 61 (62.9) 1.00 (0.63-1.57) 0.992
Underlying disease
  Diabetes mellitus 128 (28.1) 17 (17.5) 0.55 (0.31-0.96) 0.032
  Chronic liver disease 94 (20.6) 29 (29.9) 1.64 (1.01-2.68) 0.046
  Biliary tract disease 77 (16.9) 8 (8.2) 0.44 (0.21-0.95) 0.032
  Chronic kidney disease 28 (6.1) 4 (4.1) 0.66 (0.26-1.92) 0.440
  Respiratory disease 34 (7.5) 5 (5.2) 0.68 (0.26-1.77) 0.421
  Solid tumor 173 (37.9) 65 (67.0) 3.32 (2.09-5.28) <0.001
  Hematologic malignancy 16 (3.5) 11 (11.3) 3.52 (1.58-7.84) 0.003
  Solid organ transplantation 13 (2.9) 1 (1.0) 0.36 (0.05-2.75) 0.482
Charlson's WIC (≥3) 135 (29.6) 53 (54.6) 2.86 (1.83-4.48) <0.001
Primary infection site
  Urinary tract 58 (12.7) 7 (7.2) 0.53 (0.24-1.22) 0.126
  Peritoneum 42 (9.2) 15 (15.5) 1.80 (0.96-3.40) 0.066
  Pancreatobiliary tract 163 (35.7) 21 (21.6) 0.50 (0.30-0.84) 0.007
  Liver 105 (23.0) 3 (3.1) 0.11 (0.03-0.35) <0.001
  Lung 27 (5.9) 17 (17.5) 3.38 (1.76-6.48) <0.001
  Skin and soft tissue 8 (1.8) 4 (4.1) 2.41 (0.71-8.17) 0.239
  Bone 5 (1.1) 1 (1.0) 0.94 (0.11-8.13) 1.000
  Central nervous system 1 (0.2) 0 (0) 0.82 (0.79-0.86) 1.000
  Othersa 3 (0.7) 1 (1.0) 1.57 (0.16-15.28) 0.539
  Unknown 45 (9.9) 28 (28.9) 3.71 (2.17-6.34) <0.001
Metastatic infection 18 (3.9) 2 (2.1) 0.51 (0.12-2.25) 0.551
Endophthalmitis 8 (1.8) 0 (0) 0.82 (0.79-0.86) 0.362
Pitt bacteremia score (≥4) 46 (10.1) 46 (47.4) 8.04 (4.87-13.28) <0.001
Shock at presentation 97 (21.3) 59 (60.8) 5.75 (3.61-9.15) <0.001
Neutropenia at presentation 25 (5.5) 20 (20.6) 4.48 (2.37-8.46) <0.001
Healthcare-associated infection 243 (53.3) 70 (72.2) 2.27 (1.41-3.68) 0.001
Polymicrobial infection 57 (12.5) 24 (24.7) 2.30 (1.34-3.94) 0.002
Antimicrobial resistance
  non-susceptible to CIP 32 (7.0) 9 (9.3) 1.36 (0.63-2.94) 0.440
  non-susceptible to ESC 29 (6.4) 8 (8.2) 1.32 (0.59-2.99) 0.499
Inappropriate empirical antimicrobial therapy 27 (5.9) 13 (13.4) 2.46 (1.22-4.96) 0.010
Inappropriate definitive antimicrobial therapyb 12/446 (2.7) 2/55 (3.6) 1.37 (0.30-6.26) 0.659

Data indicate no. (%) of patients.

WIC, weighted index of co-morbidity; CIP, ciprofloxacin; ESC, extended-spectrum cephalosporin; OR, odds ratio; CI, confidence interval.

a Others were one appendicitis, one pericarditis and two periodontitis.

b 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).

Jung et al.

Jung et al. BMC Infectious Diseases 2012 12:239   doi:10.1186/1471-2334-12-239

Open Data